Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sima Porten

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
JCI Insight|April 29, 2025
Identification and regulation of circulating tumor-TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancerSerena S Kwek, Hai Yang, Tony Li, et al.
The Journal of Urology|August 6, 2013
Refining patient selection for neoadjuvant chemotherapy before radical cystectomyStephen H Culp, Rian J Dickstein, H Barton Grossman, et al.
Clinical Genitourinary Cancer|March 21, 2026
Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder CancerBrendan L Raizenne, Vadim S Koshkin, Alec Zhu, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2026
Functionally heterogeneous intratumoral CD4<sup>+</sup>CD8<sup>+</sup> double-positive T cells can give rise to single-positive T cellsTony Li, Arielle Ilano, Marcel Arias-Badia, et al.
Cancer Cell|February 15, 2014
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapyWoonyoung Choi, Sima Porten, Seungchan Kim, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Cell|June 5, 2020
Intratumoral CD4<sup>+</sup> T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerDavid Y Oh, Serena S Kwek, Siddharth S Raju, et al.
European Urology|October 4, 2025
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the BladderAmanda A Myers, Ruchika Talwar, Zhigang Duan, et al.
European Urology|April 12, 2021
Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate CancerCarissa E Chu, Mohammed Alshalalfa, Martin Sjöström, et al.
Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
JCI Insight|April 29, 2025
Identification and regulation of circulating tumor-TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancerSerena S Kwek, Hai Yang, Tony Li, et al.
The Journal of Urology|August 6, 2013
Refining patient selection for neoadjuvant chemotherapy before radical cystectomyStephen H Culp, Rian J Dickstein, H Barton Grossman, et al.
Clinical Genitourinary Cancer|March 21, 2026
Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder CancerBrendan L Raizenne, Vadim S Koshkin, Alec Zhu, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2026
Functionally heterogeneous intratumoral CD4<sup>+</sup>CD8<sup>+</sup> double-positive T cells can give rise to single-positive T cellsTony Li, Arielle Ilano, Marcel Arias-Badia, et al.
Cancer Cell|February 15, 2014
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapyWoonyoung Choi, Sima Porten, Seungchan Kim, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Cell|June 5, 2020
Intratumoral CD4<sup>+</sup> T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerDavid Y Oh, Serena S Kwek, Siddharth S Raju, et al.
European Urology|October 4, 2025
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the BladderAmanda A Myers, Ruchika Talwar, Zhigang Duan, et al.
European Urology|April 12, 2021
Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate CancerCarissa E Chu, Mohammed Alshalalfa, Martin Sjöström, et al.
Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.
Pageof 5